罗氏诊断宣布，美国食品药品监督管理局（FDA）已批准其与合作伙伴礼来公司的血液检测产品，可作为阿尔茨海默症初步评估的辅助手段。此次获批紧随FDA于5月批准富士瑞比欧诊断公司的Lumipulse血液检测之后，该产品是首个获准用于诊断这种脑部退行性疾病的同类设备。
罗氏诊断宣布，美国食品药品监督管理局（FDA）已批准其与合作伙伴礼来公司的血液检测产品，可作为阿尔茨海默症初步评估的辅助手段。此次获批紧随FDA于5月批准富士瑞比欧诊断公司的Lumipulse血液检测之后，该产品是首个获准用于诊断这种脑部退行性疾病的同类设备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.